About B2 bradykinin receptor
B2 bradykinin receptor (BDKRB2) is a protein
from Homo sapiens identified by UniProt accession
P30411, 391 residues long.
MolForge cross-references it against 0 known binders and
272 disease associations.
Target properties
| Protein name | B2 bradykinin receptor |
| UniProt accession | P30411 |
| Gene | BDKRB2 |
| Organism | Homo sapiens |
| Length | 391 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (3)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (272)
Diseases linked to this target (Open Targets).
- angioedema · score 0.61
- hereditary angioedema · score 0.55
- heart failure · score 0.39
- neurodegenerative disease · score 0.36
- response to angiotensin-converting enzyme inhibitor · score 0.26
- hypotension · score 0.26
- ovarian cancer · score 0.26
- creatinine measurement · score 0.25
- breast adenocarcinoma · score 0.25
- subcutaneous adipose tissue measurement · score 0.24
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P30411-F1 | alphafold | PREDICTED | 79.51 | — |
Amino-acid sequence (391 residues)
MFSPWKISMF LSVREDSVPT TASFSADMLN VTLQGPTLNG TFAQSKCPQV EWLGWLNTIQ PPFLWVLFVL ATLENIFVLS VFCLHKSSCT VAEIYLGNLA AADLILACGL PFWAITISNN FDWLFGETLC RVVNAIISMN LYSSICFLML VSIDRYLALV KTMSMGRMRG VRWAKLYSLV IWGCTLLLSS PMLVFRTMKE YSDEGHNVTA CVISYPSLIW EVFTNMLLNV VGFLLPLSVI TFCTMQIMQV LRNNEMQKFK EIQTERRATV LVLVVLLLFI ICWLPFQIST FLDTLHRLGI LSSCQDERII DVITQIASFM AYSNSCLNPL VYVIVGKRFR KKSWEVYQGV CQKGGCRSEP IQMENSMGTL RTSISVERQI HKLQDWAGSR Q
Explore B2 bradykinin receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets